Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling

Area of Science:

• Oncology
• Molecular Diagnostics
• Genomics

Background:

• Liquid biopsies, particularly cell-free DNA (cfDNA), offer a less invasive alternative to tissue biopsies for cancer detection and monitoring.
• Next Generation Sequencing (NGS) cfDNA assays are increasingly used in clinical practice, but their clinical validity and utility require further proof.

Purpose of the Study:

• To evaluate the performance of commercially available reference materials and cfDNA from Diagnostic Leukaphereses (DLA) for assessing mutation analysis platforms.
• To compare the inter- and intra-assay, and intra- and inter-laboratory performance of various cfDNA testing methods.

Main Methods:

• Utilized commercially available reference materials and DLA samples in three experimental setups.
• Tested a range of assays including digital droplet PCR (ddPCR), MassARRAY, and various NGS-based assays.
• Performed inter- and intra-assay, and intra- and inter-laboratory comparisons.

Main Results:

• Both reference materials with predetermined variant allele frequencies (VAFs) and DLA samples proved highly useful for performance assessment.
• Demonstrated substantial variability in sensitivity and specificity among different NGS assays.
• Highlighted the critical need for extensive test performance validation.

Conclusions:

• Reference materials and DLA samples are valuable tools for validating cfDNA mutation analysis platforms.
• Significant variability in NGS assay performance underscores the necessity of rigorous validation before clinical implementation.
• Further standardization and validation are essential for reliable cfDNA testing in cancer care.